Published: 1/18/2022 10:56:34 AM
Redeye endorses ISAB submitting a whitepaper to the FDA in order to establish the DissolvIt lung model as an FDA-recommended standard research method in the US. We see an interesting year ahead and continue to argue that the share is attractive at current share price levels.
Link to the analysis